Table 1.
Demographics and disease characteristics at start of follow-up
| AS (n = 8517) |
AS controls (n = 39369) |
uSpA (n = 10245) |
uSpA controls (n = 46903) |
PsA (n = 22667) |
PsA controls (n = 99254) |
|
|---|---|---|---|---|---|---|
| Men | 5771 (67.8) | 26226 (66.6) | 4557 (44.5) | 20767 (44.3) | 10520 (46.4) | 45315 (45.7) |
| Age at start, mean (s.d.) | 47 (13) | 47 (13) | 42 (13) | 42 (13) | 50 (12) | 50 (12) |
| 18–29 years | 990 (11.6) | 4585 (11.6) | 2009 (19.6) | 8947 (19.1) | 1582 (7.0) | 7177 (7.2) |
| 30–39 years | 1649 (19.4) | 7444 (18.9) | 2690 (26.3) | 11879 (25.3) | 3346 (14.8) | 14503 (14.6) |
| 40–49 years | 2019 (23.7) | 9315 (23.7) | 2617 (25.5) | 12069 (25.7) | 5415 (23.9) | 23115 (23.3) |
| 50–59 years | 2161 (25.4) | 10001 (25.4) | 1915 (18.7) | 9111 (19.4) | 6734 (29.7) | 29230 (29.4) |
| 60–69 years | 1698 (19.9) | 8024 (20.4) | 1014 (9.9) | 4897 (10.4) | 5590 (24.7) | 25229 (25.4) |
| Medicationa | ||||||
|
DMARDs csDMARDs TNFi |
2404 (28.2) 1672 (19.6) 1098 (12.9) |
267 (0.7) 257 (0.7) 29 (0.1) |
3224 (31.5) 2701 (26.4) 887 (8.7) |
320 (0.7) 300 (0.6) 35 (0.1) |
10612 (46.8) 10084 (44.5) 1338 (5.9) |
812 (0.8) 771 (0.8) 82 (0.1) |
| NSAIDs | 5021 (59.0) | 3558 (9.0) | 5950 (58.1) | 3986 (8.5) | 11685 (51.6) | 10064 (10.1) |
| Glucocorticoids | 1032 (12.1) | 865 (2.2) | 1760 (17.2) | 1014 (2.2) | 4027 (17.8) | 2732 (2.8) |
| Prior extra-articular manifestations | ||||||
| Anterior uveitis (AU)b | 1852 (21.7) | 215 (0.5) | 1498 (14.6) | 237 (0.5) | 356 (1.6) | 630 (0.6) |
|
AU, ophthalmology care Chronic AU within 5 yearsb AU flare within 5 years One flare Two flares Three flares ≥ Four flares |
1840 (21.6) 151 (1.8) 1488 (17.5) 701 (8.2) 384 (4.5) 209 (2.5) 206 (2.4) |
210 (0.5) 13 (0.0) 131 (0.3) 94 (0.2) 21 (0.1) 10 (0.0) 6 (0.0) |
1491 (14.6) 154 (1.5) 1205 (11.8) 548 (5.3) 322 (3.1) 137 (1.3) 198 (1.9) |
236 (0.5) 19 (0.0) 148 (0.3) 99 (0.2) 28 (0.1) 8 (0.0) 13 (0.0) |
348 (1.5) 37 (0.2) 250 (1.1) 158 (0.7) 45 (0.2) 21 (0.1) 26 (0.1) |
615 (0.6) 50 (0.1) 411 (0.4) 285 (0.3) 63 (0.1) 29 (0.0) 34 (0.0) |
| IBDb | 615 (7.2) | 411 (1.0) | 632 (6.2) | 511 (1.1) | 504 (2.2) | 1166 (1.2) |
| IBD, internal medicine, gastroenterology or surgery care | 592 (7.0) | 391 (1.0) | 595 (5.8) | 496 (1.1) | 466 (2.1) | 1134 (1.1) |
| CD | 230 (2.7) | 102 (0.3) | 212 (2.1) | 162 (0.3) | 170 (0.7) | 358 (0.4) |
| UC | 273 (3.2) | 236 (0.6) | 277 (2.7) | 267 (0.6) | 234 (1.0) | 657 (0.7) |
| Overlap CD and UC | 89 (1.0) | 53 (0.1) | 106 (1.0) | 67 (0.1) | 62 (0.3) | 119 (0.1) |
| Psoriasisb | 264 (3.1) | 589 (1.5) | 405 (4.0) | 610 (1.3) | n.a. | 1740 (1.8) |
| Psoriasis according to NPR | 224 (2.6) | 417 (1.1) | 340 (3.3) | 452 (1.0) | 1218 (1.2) | |
| Psoriasis according to PDR | 100 (1.2) | 322 (0.8) | 152 (1.5) | 313 (0.7) | 1011 (1.0) | |
Data is presented as number (%) if not stated otherwise.
Medication is defined as ≥1 dispensed prescription in Prescribed Drug Register within 6 months before start of follow-up. Intravenous TNFi were identified through the Swedish Rheumatology Quality Register.
Exclusion criteria for the incident AU, AU flares, incident IBD and incident psoriasis analysis, respectively.
CD: Crohn’s disease; csDMARDs: conventional synthetic DMARDs; n.a.: not applicable; NPR: National Patient Register; PDR: Prescribed Drug Register; TNFi: TNF inhibitors; uSpA: undifferentiated SpA; UC: ulcerative colitis.